Parkside Financial Bank & Trust Increases Stock Position in GSK plc (NYSE:GSK)

Parkside Financial Bank & Trust boosted its holdings in GSK plc (NYSE:GSK) by 470.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 992 shares of the pharmaceutical company’s stock after purchasing an additional 818 shares during the quarter. Parkside Financial Bank & Trust’s holdings in GSK were worth $34,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. Gladstone Institutional Advisory LLC raised its holdings in shares of GSK by 13.6% in the third quarter. Gladstone Institutional Advisory LLC now owns 11,814 shares of the pharmaceutical company’s stock valued at $483,000 after buying an additional 1,410 shares during the last quarter. Van ECK Associates Corp grew its holdings in shares of GSK by 8.4% during the third quarter. Van ECK Associates Corp now owns 736,510 shares of the pharmaceutical company’s stock worth $27,973,000 after buying an additional 56,843 shares during the last quarter. BSW Wealth Partners acquired a new position in GSK in the 3rd quarter valued at about $223,000. Forum Financial Management LP purchased a new stake in GSK during the 3rd quarter valued at approximately $204,000. Finally, KG&L Capital Management LLC lifted its position in GSK by 44.1% during the 3rd quarter. KG&L Capital Management LLC now owns 16,685 shares of the pharmaceutical company’s stock worth $679,000 after acquiring an additional 5,104 shares during the period. Institutional investors and hedge funds own 15.74% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. StockNews.com raised GSK from a “buy” rating to a “strong-buy” rating in a report on Friday, February 7th. Jefferies Financial Group cut shares of GSK from a “buy” rating to a “hold” rating and dropped their price objective for the company from $53.00 to $39.50 in a research note on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft cut shares of GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Finally, Morgan Stanley initiated coverage on shares of GSK in a research note on Wednesday, February 12th. They set an “equal weight” rating on the stock. Seven equities research analysts have rated the stock with a hold rating and four have issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $43.25.

GSK Price Performance

GSK stock opened at $37.97 on Tuesday. The company has a market cap of $78.70 billion, a P/E ratio of 23.88, a price-to-earnings-growth ratio of 1.12 and a beta of 0.64. GSK plc has a one year low of $31.72 and a one year high of $45.92. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78. The business has a fifty day moving average of $35.07 and a two-hundred day moving average of $37.20.

GSK (NYSE:GSK) last issued its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. As a group, analysts predict that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, April 10th. Shareholders of record on Friday, February 21st will be given a dividend of $0.3932 per share. This represents a $1.57 dividend on an annualized basis and a yield of 4.14%. The ex-dividend date is Friday, February 21st. This is an increase from GSK’s previous quarterly dividend of $0.39. GSK’s payout ratio is 98.74%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.